Dali Pharmaceuticalco.,Ltd

SHSE:603963 Stok Raporu

Piyasa değeri: CN¥645.9m

Dali Pharmaceuticalco.Ltd Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Dali Pharmaceuticalco.Ltd has a total shareholder equity of CN¥361.4M and total debt of CN¥19.3M, which brings its debt-to-equity ratio to 5.4%. Its total assets and total liabilities are CN¥450.2M and CN¥88.8M respectively.

Anahtar bilgiler

5.4%

Borç/özkaynak oranı

CN¥19.34m

Borç

Faiz karşılama oranın/a
NakitCN¥207.69m
EşitlikCN¥361.39m
Toplam yükümlülüklerCN¥88.81m
Toplam varlıklarCN¥450.20m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Some Confidence Is Lacking In Dali Pharmaceuticalco.,Ltd (SHSE:603963) As Shares Slide 46%

Apr 22
Some Confidence Is Lacking In Dali Pharmaceuticalco.,Ltd (SHSE:603963) As Shares Slide 46%

Dali Pharmaceuticalco.,Ltd's (SHSE:603963) 29% Price Boost Is Out Of Tune With Revenues

Mar 08
Dali Pharmaceuticalco.,Ltd's (SHSE:603963) 29% Price Boost Is Out Of Tune With Revenues

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 603963's short term assets (CN¥273.3M) exceed its short term liabilities (CN¥77.3M).

Uzun Vadeli Yükümlülükler: 603963's short term assets (CN¥273.3M) exceed its long term liabilities (CN¥11.5M).

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 603963 has more cash than its total debt.

Borcun Azaltılması: 603963's debt to equity ratio has increased from 0% to 5.4% over the past 5 years.

Borç Kapsamı: 603963's operating cash flow is negative, therefore debt is not well covered.

Faiz Kapsamı: Insufficient data to determine if 603963's interest payments on its debt are well covered by EBIT.

Bilanço

Sağlıklı şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y